Vaxart Plunges 60% on Concerns of the Effectiveness of Oral Covid Vaccine
Vaxart’s stock fell 60% after the company failed to find neutralizing antibodies in clinical trials of its oral Covid vaccine, according to CNBC. The disappointing results came even as the…